Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cordlife GroupCLIFF 41 Revenue per Share is $0.11 as of Jun. 2026. GuruFocus rates CLIFF with a GF Score™ of 41/100 and a GF Value™ of $0.16. The stock has 4 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Cordlife Group ranks worse than 66.32% on this metric.
Cordlife Group's revenue per share for the
three
months ended in Jun. 2026 was $0.03.
Cordlife Group's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.11.
Warning Sign:
Cordlife Group Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Cordlife Group was -1.40% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -10.90% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -11.30% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was -3.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Cordlife Group's Revenue per Share or its related term are showing as below:
CLIFF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -21.2 Med: 0 Max: 15.6
Current: -10.9
During the past 13 years, Cordlife Group's highest 3-Year average Revenue Per Share Growth Rate was 15.60% per year. The lowest was -21.20% per year. And the median was 0.00% per year.
CLIFF's 3-Year Revenue Growth Rate is ranked worse than 66.32% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.7
vs CLIFF: -10.90
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Cordlife Group Revenue per Share Related Terms
Cordlife Group Revenue per Share Historical Data
* Premium members only.
The historical data trend for Cordlife Group's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLIFF vs TMO, DHR, NTRA: Revenue per Share Comparison
For the Diagnostics & Research subindustry, Cordlife Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cordlife Group's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Cordlife Group's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.11
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cordlife Group (CLIFF) has a Revenue per Share of $0.11 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Cordlife Group and its competitors. According to the industry distribution chart, Cordlife Group ranks #126 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 66.3%.
Is Cordlife Group's Revenue per Share too high?
Cordlife Group's current Revenue per Share is $0.11. The Medical Diagnostics & Research industry median Revenue per Share is 1.70. Cordlife Group's value of $0.11 is 93.5% below this industry median. Based on the distribution chart, Cordlife Group ranks #126 out of 190 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Cordlife Group has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's Revenue per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #126 out of 190 companies for Revenue per Share. This places Cordlife Group in the lower half of its industry. The industry median Revenue per Share is 1.70. Cordlife Group's value of $0.11 is 93.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Diagnostics & Research company?
The median Revenue per Share among Medical Diagnostics & Research companies is 1.70, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cordlife Group's current Revenue per Share of $0.11 is 93.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Cordlife Group and its competitors. For the Medical Diagnostics & Research industry, the median Revenue per Share is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cordlife Group's current Revenue per Share is $0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Cordlife Group (CLIFF) has a current Revenue per Share of $0.11. The stock's GF Value™ is $0.16, compared to a current price of $0.15 — trading 6% below its estimated fair value. The current Revenue per Share is $0.11 and 93.5% below the Medical Diagnostics & Research industry median of 1.70. Cordlife Group's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current Revenue per Share is $0.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be undervalued.
The current stock price of $0.15 is trading 6% below its estimated GF Value™ of $0.16.
Key valuation signals for CLIFF:
Revenue per Share: $0.11
GF Value™: $0.16 vs. price of $0.15 (6% below fair value)
Industry Position: 93.5% below the Medical Diagnostics & Research median (#126 of 190)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
41GF Score
Get the complete analysis for CLIFF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 
